课题基金 / 基金详情

Tadalafil Induced Modulation of Immune Response in HNSCC

Tadalafil Induced Modulation of Immune Response in HNSCC
他达拉非诱导 HNSCC 免疫反应的调节
批准号:
7753171
负责人:
Joseph A Califano
金额:
$36.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-01-01 至 2012-12-31

项目摘要

项目成果

Joseph A Califano的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tadalafil induced modulation of immune response in HNSCC Head and neck squamous cell carcinoma (HNSCC) affects over 40,000 individuals per year in the United States, however cure rates for advanced disease hover around 50%. HNSCC patients demonstrate significant impairment in immune recognition of tumor cells, and evasion from immune response is a significant factor in HNSCC carcinogenesis. Preliminary data from our laboratory suggest that mature CD11b+/GR1+ myeloid derived suppressor cells (MDSC)s induce a suppressive phenotype resulting in tumor-specific T cell anergy in both CD4+ and CD8+ T-cells in HNSCC, and that functional elimination of MDSCs via phosphodiesterase 5 (PDE5) inhibitors can restore T cell function in lymphocytes from HNSCC patients. This study will examine the candidacy of tadalafil as an immunotherapeutic agent to reverse MDSC mediated suppression of T cell function in patients with HNSCC. PUBLIC HEALTH RELEVANCE: Head and neck squamous cell carcinoma (HNSCC)is associated with cure rate of approximately 50% and evasion from immune response is a significant factor in HNSCC carcinogenesis. This study will examine the candidacy of tadalafil as an immunotherapeutic agent to reverse suppression of T cell function in patients with HNSCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer
Optimizing immunoradiotherapy for HNSCC
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer
Optimizing an assay for high risk HPV DNA in body fluids
海外基金